Retatrutide

An investigational triple-receptor agonist (GLP-1/GIP/glucagon) being studied in Phase 3 trials for weight management.

Status: Investigational — not FDA-approved. It cannot currently be legally prescribed, sold as a medicine, or compounded. Products sold online as "retatrutide" are unapproved and unverified.

Unlike current medications that usually target one or two hormone pathways (like GLP-1 and sometimes GIP), retatrutide is designed to activate three receptors at once:

• GLP-1 receptor – helps regulate blood sugar, appetite, and gastric emptying

• GIP receptor – involved in insulin secretion and energy balance

• Glucagon receptor – influences energy expenditure and fat metabolism

Because of this, you’ll sometimes see it referred to as a “triple agonist” or “Triple G.”

Retatrutide is being studied as a once-weekly injection that acts on three hormonal systems:

1. Appetite & Satiety (GLP-1, GIP)

   • Signals the brain that you’re full sooner and for longer

   • Reduces cravings and overall calorie intake

2. Blood Sugar & Insulin (GLP-1, GIP)

   • Enhances insulin secretion when blood sugar is elevated

   • Reduces glucagon (from the pancreas), which normally raises blood sugar

   • Helps improve insulin sensitivity and glycemic control in people with type 2 diabetes

3. Energy Expenditure & Fat Metabolism (Glucagon receptor)

   • Glucagon signaling can increase energy expenditure

   • May help the body mobilize and burn stored fat

The idea: by hitting three levers at once, retatrutide could potentially deliver greater weight loss and metabolic improvements than current single- or dual-agonist drugs. This is still being tested and is not yet proven in long-term, real-world use.

Phase 2 Obesity Trial

A phase 2 clinical trial in adults with obesity (no diabetes) showed very large average weight reductions over 48 weeks at higher doses:

• At 48 weeks:

  • Around 22.8% mean weight loss at 8 mg

  • Around 24.2% mean weight loss at 12 mg

• More than 90% of participants on higher doses lost at least 10% of their body weight in some analyses.

These numbers are trial averages, in highly selected, closely monitored participants. They don’t guarantee individual results and don’t replace long-term safety data.

Metabolic & Liver Effects

Sub-studies suggest potential benefits beyond the scale, including:

• Reductions in liver fat in people with metabolic dysfunction–associated steatotic liver disease (MASLD)

• Improvements in cardiometabolic risk factors (like blood sugar and some lipid parameters)

Again: this is early-stage, controlled research – not everyday clinical experience.

Short answer: no.

• As of Summer of 2026, Retatrutide is not approved by the U.S. FDA for any condition.

• It is currently in phase 3 clinical trials, which are expected to finish around Fall of 2026 if there are no major delays.

• Only after successful completion of these trials can the manufacturer apply for FDA approval, and regulatory review can take many months to years.

There is no guarantee that Retatrutide will be approved, what dose will be chosen, what indications it will have, or what safety warnings it might carry.

In early studies, retatrutide has shown even greater average weight loss than currently approved agents (like semaglutide and tirzepatide) over similar time frames – sometimes exceeding 20–24% average loss at ~1 year at higher doses.

However:

• These are indirect comparisons across different trials, not head-to-head studies.

• We still lack:

  • Long-term cardiovascular outcome data

  • Extensive real-world safety data

  • Information on regain after stopping the drug

For now, retatrutide should be seen as a promising, experimental next-generation option, not a replacement for established, FDA-approved therapies.

To be absolutely clear about our stance:

• We do NOT prescribe, sell, or include Retatrutide in any of our weight loss or longevity programs.

• We do NOT use compounded Retatrutide or “research” versions – these are specifically flagged by the FDA as unapproved and not allowed in compounding.

• We follow evidence-based, FDA-approved options for weight management, paired with:

  • Personalized nutrition support

  • Hormonal and metabolic evaluation where appropriate

  • Long-term lifestyle strategies for sustainable change

We do stay current with emerging research, including Retatrutide and other multi-agonist medications, so we can help you understand what’s coming and how it may shape the future of obesity and metabolic care.

If you’re curious about where a drug like Retatrutide might fit for you in theory, that’s a conversation to have with your own prescribing clinician once (and if) it becomes approved and available through legal, regulated channels.

This page is for educational purposes only. It does not offer medical advice, diagnosis, treatment, or endorsement of retatrutide. Always consult your own licensed healthcare provider before starting, stopping, or changing any medication or weight loss therapy.